Wastewater testing has flagged a sharp rise in human metapneumovirus on the West Coast, with clusters concentrated around San Francisco and nearby Northern California communities; the outbreak climbed steeply in January and remains elevated into March even as the typical winter wave eases. Public health wastewater surveillance, clinical reports and expert commentary point to a contagious respiratory virus that behaves like other seasonal pathogens, hits vulnerable groups hardest, and currently has no targeted vaccine or antiviral treatment. This article walks through where the signals are strongest, what infections tend to look like, who is at greatest risk, and what basic care and prevention options are available.
Local wastewater SCAN data show human metapneumovirus, commonly called HMPV, circulating broadly across Northern California communities including San Francisco, Marin, Vallejo, Napa, Novato, Santa Rosa, Sacramento and Davis. The pattern hit a sharp peak in January and, while the winter surge is loosening its grip, levels in early March remain noticeably elevated compared with typical seasonal baselines. These wastewater signals give an early, population-level view of rising infections even before every case shows up in hospitals or clinics.
The Centers for Disease Control and Prevention’s National Wastewater Surveillance System tracks viral and bacterial signals in sewage to map infection patterns across communities and regions. Wastewater monitoring doesn’t replace clinical testing, but it complements lab data by revealing trends in near real time, often picking up increases in household transmission before outpatient volumes spike. That broader lens is why public health professionals pay attention to rising HMPV markers coming out of both the West Coast and other regions.
“It is a single-stranded RNA virus, like flu and COVID,” Dr. Marc Siegel, Fox News senior medical analyst, told Fox News Digital. The expert note underscores that HMPV joins a family of common respiratory RNA viruses that move efficiently through close contact and respiratory droplets. Clinicians and public health teams treat HMPV as part of the seasonal respiratory mix that can overlap with influenza, RSV and other pathogens.
The wastewater trends are not isolated to California; data indicate upticks in the Midwest and Northeast as well, suggesting a more widespread seasonal push. That geographic spread is consistent with how respiratory viruses travel through travel, household chains and congregate settings during colder months and the transition into spring. Public health officials track these regional patterns to anticipate hospital burdens and advise clinicians on testing priorities.
In otherwise healthy children and adults, HMPV most often causes cough, fever, nasal congestion and shortness of breath, mirroring common respiratory infections in both symptoms and course. People at highest risk of severe outcomes include young children, older adults and those with weakened immune systems, and the infection contributes to significant global hospitalizations each year—an estimated 650,000 admissions worldwide according to clinical commentary. When HMPV progresses, it can lead to pneumonia and other serious respiratory complications requiring supportive medical care.
Less common but important complications listed by clinical authorities include asthma exacerbations, wheezing, breathing difficulty, bronchiolitis, ear infections, croup and fevers that can be intense in small children. Adults with chronic lung disease such as chronic obstructive pulmonary disease may see their baseline condition worsen if they catch HMPV. Because these secondary effects can escalate quickly in vulnerable patients, clinicians often monitor oxygen levels and hydration closely and escalate care when breathing gets harder.
The virus spreads primarily through close personal contact, respiratory droplets from coughing and sneezing, and contact with contaminated surfaces, which is why it tends to peak from winter through spring when indoor crowding increases. There is currently no vaccine or specific antiviral treatment for HMPV, and diagnosis depends on clinical testing ordered by a healthcare provider when symptoms and exposure history suggest it. Supportive care remains the standard approach: rest, fluids and symptom management, while public health agencies advise simple prevention steps to help curb spread in communities and households.
